Grufity logoGrufity logo

Ionis Pharmaceuticals Inc Stock Research

IONS

35.00USD+0.81(+2.37%)Market Closed

Market Summary

USD35.00+0.81
Market Closed
2.37%

IONS Alerts

IONS Stock Price

IONS RSI Chart

IONS Valuation

Market Cap

5.0B

Price/Earnings (Trailing)

-18.43

Price/Sales (Trailing)

8.46

EV/EBITDA

-19.94

Price/Free Cashflow

-17.14

IONS Price/Sales (Trailing)

IONS Profitability

EBT Margin

-43.92%

Return on Equity

-47.08%

Return on Assets

-10.64%

Free Cashflow Yield

-5.83%

IONS Fundamentals

IONS Revenue

Revenue (TTM)

587.4M

Revenue Y/Y

-65.48%

Revenue Q/Q

-4.93%

IONS Earnings

Earnings (TTM)

-269.7M

Earnings Y/Y

-123.34%

Earnings Q/Q

-11.57%

Price Action

52 Week Range

31.4648.82
(Low)(High)

Last 7 days

-4.0%

Last 30 days

-13.8%

Last 90 days

-10.5%

Trailing 12 Months

4.6%

IONS Financial Health

Current Ratio

7.07

IONS Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-1.9

Peers (Alternatives to Ionis Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
304.8B
1.4B
-3.73% 61.04%
-152.12
215.28
20.37% -37.45%
275.0B
58.1B
0.21% 1.63%
23.24
4.74
3.30% 2.55%
80.1B
12.2B
-0.48% 14.17%
18.47
6.58
-24.26% -46.28%
77.3B
8.9B
-1.64% 19.14%
23.26
8.65
17.91% 41.84%
23.5B
1.0B
-16.46% 21.47%
-20.78
22.66
22.88% -32.64%
13.2B
933.0M
21.02% 90.98%
-18.71
14.11
32.93% -67.99%
10.1B
1.9B
-15.04% 21.63%
13.93
5.23
14.88% 52.86%
MID-CAP
4.5B
504.0K
-6.48% 165.34%
-15.07
2.5K
-66.53% -22.12%
2.8B
363.3M
-7.03% -36.05%
-3.99
7.77
3.39% -55.81%
2.7B
204.0M
2.71% -22.88%
-4.84
13.22
13.30% 13.44%
2.5B
12.4M
-10.70% -44.17%
-3.35
199.44
- -27.34%
SMALL-CAP
1.6B
191.8M
-7.72% 90.19%
24.49
8.55
43.59% 60.82%
429.6M
93.0M
-0.16% -22.78%
-2.25
4.62
-19.83% -30.37%
24.0M
-
-31.83% 665.59%
-0.57
19.11
-77.61% 7.22%
3.5M
94.6M
-15.04% 9.81%
-0.01
0.04
34.30% -80.65%

Financials for Ionis Pharmaceuticals

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-32.9%587,367,000875,483,000848,809,000840,768,000810,456,000
  S&GA Expenses7.4%150,295,000139,945,000136,622,000159,275,000186,347,000
EBITDA-772.7%-235,535,00035,013,000-1,953,00020,852,000-
EBITDA Margin-1102.7%-0.400.040.000.02-
Earnings Before Taxes-2391.0%-257,985,00011,261,000-25,803,000-3,476,000-29,148,000
EBT Margin-3514.6%-0.440.01-0.030.00-
Interest Expenses-5.9%8,122,0008,629,0008,830,0009,057,0009,349,000
Net Income-3784.2%-269,722,0007,321,000-28,153,000-3,893,000-28,597,000
Net Income Margin-5591.6%-0.460.01-0.030.00-
Free Cahsflow-351.3%-290,091,000115,428,00086,502,00040,923,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets4.6%2,5342,4222,4562,5192,612
  Current Assets2.3%2,2032,1522,1912,2532,345
    Cash Equivalents-12.2%276315522543869
  Inventory6.7%22.0021.0020.0024.0025.00
  Net PPE-58.9%74.00181177178178
Liabilities7.3%1,9611,8281,8311,8101,840
  Current Liabilities9.9%312283268228241
Shareholder's Equity-3.6%573594625710772
  Retained Earnings-3.8%-1,429-1,377-1,330-1,225-1,159
  Additional Paid-In Capital1.2%2,0602,0352,0091,9831,964
Accumulated Depreciation-103----
Shares Outstanding0.0%142142142142141
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-311.8%-27413098.0054.0031.00
  Share Based Compensation3.5%10097.00104109121
Cashflow From Investing30.8%-262-379-73.77-171195
Cashflow From Financing17.2%-55.29-66.77-67.14246246
  Buy BacksNaN%0.000.00---

Risks for IONS

What is the probability of a big loss on IONS?

90%


Probability that Ionis Pharmaceuticals stock will be more than 20% underwater in next one year

65.4%


Probability that Ionis Pharmaceuticals stock will be more than 30% underwater in next one year.

21.1%


Probability that Ionis Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IONS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ionis Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for IONS

Cumulative Returns on IONS

-1.1%


7-Year Cumulative Returns

-7.9%


5-Year Cumulative Returns

-10.9%


3-Year Cumulative Returns

What are the long-term rolling returns for IONS?

FIve years rolling returns for Ionis Pharmaceuticals.

Annualized Returns

Which funds bought or sold IONS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
19.15
4,959
329,959
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.05
-102,725
596,275
-%
2023-03-10
BAILLIE GIFFORD & CO
added
2.75
-1,760,830
12,607,200
0.01%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
unchanged
-
-88,306
516,694
0.03%
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
-17,000
97,000
-%
2023-02-28
Voya Investment Management LLC
added
-
-453,638
2,654,360
-%
2023-02-24
NATIXIS
added
19.09
93,038
6,031,040
0.03%
2023-02-24
SRS Capital Advisors, Inc.
reduced
-59.46
-1,433
567
-%
2023-02-21
MACQUARIE GROUP LTD
unchanged
-
17,000
4,110,000
-%
2023-02-21
MACQUARIE GROUP LTD
added
78.85
19,376,000
56,341,000
0.07%

1–10 of 43

Latest Funds Activity

Are funds buying IONS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own IONS
No. of Funds

Ionis Pharmaceuticals News

Morningstar

10 Undervalued Quality Healthcare Stocks.

Morningstar,
23 hours ago

InvestorsObserver

The Associated Press

Ionis Pharmaceuticals: Q4 Earnings Snapshot.

The Associated Press,
23 days ago

Schedule 13G FIlings of Ionis Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
bb biotech ag
6.8%
9,635,000
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
8.2%
11,678,259
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.54%
13,546,694
SC 13G/A
Feb 01, 2023
blackrock inc.
6.5%
9,182,911
SC 13G/A
Apr 11, 2022
price t rowe associates inc /md/
10.1%
14,350,460
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
8.8%
12,490,280
SC 13G/A
Feb 11, 2022
bb biotech ag
7.2%
10,232,973
SC 13G/A
Feb 10, 2022
vanguard group inc
8.50%
12,007,076
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

IONS Fair Value

Ionis Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Ionis Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

4.15

-88.14%

5.44

-84.46%

11.00

-68.57%

20.99

-40.03%

25.62

-26.80%
Current Inflation

3.91

-88.83%

5.05

-85.57%

9.94

-71.60%

18.60

-46.86%

22.56

-35.54%
Very High Inflation

3.60

-89.71%

4.55

-87.00%

8.66

-75.26%

15.76

-54.97%

18.95

-45.86%

Historical Ionis Pharmaceuticals Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Ionis Pharmaceuticals

View All Filings
Date Filed Form Type Document
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Feb 22, 2023
8-K
Current Report
Feb 22, 2023
10-K
Annual Report
Feb 14, 2023
5
Insider Trading
Feb 14, 2023
SC 13G
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for IONS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-28
O'NEIL PATRICK R.
acquired
9,185
30.515
301
evp clo & general counsel
2023-02-28
HOUGEN ELIZABETH L
acquired
4,973
30.515
163
evp, finance & cfo
2023-02-28
BENNETT C FRANK
acquired
11,687
30.515
383
evp, chief scientific officer
2023-02-28
Swayze Eric
acquired
17,546
30.515
575
evp research
2023-02-28
Geary Richard S
acquired
17,546
30.515
575
evp, chief development officer
2023-02-06
HOUGEN ELIZABETH L
sold
-84,392
40.5927
-2,079
evp, finance & cfo
2023-02-06
Cadoret-Manier Onaiza
sold
-58,996
40.6595
-1,451
evp, chf gl pdt str & oper ofc
2023-02-06
Geary Richard S
sold
-78,070
40.6615
-1,920
evp, chief development officer
2023-02-06
Schneider Eugene
sold
-57,464
40.6682
-1,413
evp, chf clinical develop ofcr
2023-02-06
BENNETT C FRANK
sold
-73,560
40.5738
-1,813
evp, chief scientific officer

1–10 of 50

Brett P. Monia
660
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Revenue$ 587,367$ 810,456$ 729,264
Expenses:   
Cost of sales14,11610,84211,947
Research, development and patent833,147643,453535,077
Selling, general and administrative150,295186,347354,322
Total operating expenses997,558840,642901,346
Loss from operations(410,191)(30,186)(172,082)
Other income (expense):   
Investment income25,33110,04430,562
Interest expense(8,122)(9,349)(9,510)
Gain (loss) on investments(7,333)10,10316,540
Gain on sale of real estate assets149,60400
Other expenses(7,274)(9,760)(62)
Loss before income tax benefit (expense)(257,985)(29,148)(134,552)
Income tax benefit (expense)(11,737)551(345,191)
Net loss(269,722)(28,597)(479,743)
Net loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.0035,480
Net loss attributable to Ionis Pharmaceuticals, Inc. common stockholders$ (269,722)$ (28,597)$ (444,263)
Basic net loss per share (in dollars per share)$ (1.9)$ (0.2)$ (3.18)
Shares used in computing basic net loss per share (in shares)141,848141,021139,612
Diluted net loss per share (in dollars per share)$ (1.9)$ (0.2)$ (3.18)
Shares used in computing diluted net loss per share (in shares)141,848141,021139,612
Commercial Revenue [Member]   
Revenue:   
Revenue$ 303,358$ 342,395$ 364,699
SPINRAZA Royalties [Member]   
Revenue:   
Revenue242,314267,776286,583
TEGSEDI and WAYLIVRA Revenue, Net [Member]   
Revenue:   
Revenue30,05155,50069,999
Licensing and Other Royalty Revenue [Member]   
Revenue:   
Revenue30,99319,1198,117
Research and Development Revenue [Member]   
Revenue:   
Revenue284,009468,061364,565
Collaborative Agreement Revenue [Member]   
Revenue:   
Revenue207,222468,061364,565
Eplontersen Joint Development Revenue [Member]   
Revenue:   
Revenue$ 76,787$ 0$ 0

IONS Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 276,472$ 869,191
Short-term investments1,710,3971,245,782
Contracts receivable25,53861,896
Inventories22,03324,806
Other current assets168,254143,374
Total current assets2,202,6942,345,049
Property, plant and equipment, net74,294178,069
Right-of-use assets181,54417,974
Deposits and other assets75,34470,598
Total assets2,533,8762,611,690
Current liabilities:  
Accounts payable17,92111,904
Accrued compensation49,17838,810
Accrued liabilities140,10188,560
Income taxes payable6,24936
Current portion of deferred contract revenue90,57797,714
Other current liabilities7,5353,526
Total current liabilities311,561240,550
Long-term deferred contract revenue287,768351,879
Long-term lease liabilities178,94119,432
Long-term mortgage debt8,84759,713
Long-term obligations7,1266,946
Total liabilities1,960,9891,839,953
Stockholders' equity:  
Common stock, $0.001 par value; 300,000,000 shares authorized, 142,057,736 and 141,210,015 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively142141
Additional paid-in capital2,059,8501,964,167
Accumulated other comprehensive loss(57,480)(32,668)
Accumulated deficit(1,429,625)(1,159,903)
Total stockholders' equity572,887771,737
Total liabilities and stockholders' equity2,533,8762,611,690
0 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net622,242619,119
0.125 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net$ 544,504$ 542,314